PROBLEM TO BE SOLVED: To provide a novel crystalline form of a drug substance for therapy of Huntington disease.SOLUTION: A 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine (pridopidine) hydrochloride has a crystalline form, and the crystalline form is a crystalline form II characterized by X-ray powder diffraction pattern having reflections corresponding to spacing d values of 8.9, 7.7, 6.7, 6.1, 5.1, 4.9, 4.3, 4.1 and 3.6. A 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine hydrochloride that is a crystalline form II starts endotherm at about 210°C by a DSC measurement. A method of administering the compound crystal type II to remedy, prevent or alleviate dopamine mediated disorders of animals including humane beings.SELECTED DRAWING: None【課題】ハンチントン病治療のための薬物物質の新規な結晶性形態の提供。【解決手段】結晶性形態の４－（３－メタンスルホニル－フェニル）－１－プロピル－ピペリジン（プリドピジン）塩酸塩であって、前記結晶性形態が、面間隔ｄ値８．９、７．７、６．７、６．１、５．１、４．９、４．３、４．１および３．６に対応する反射を有するＸ線粉末回折パターンにより特徴づけられる結晶形態ＩＩである、４－（３－メタンスルホニル－フェニル）－１－プロピル－ピペリジン塩酸塩。ＤＳＣ測定で、約２１０℃で吸熱を開始する結晶形能ＩＩである４－（３－メタンスルホニル－フェニル）－１－プロピル－ピペリジン塩酸塩。ヒトを含めた動物のドーパミン媒介障害の治療、予防又は軽減に前記化合物結晶型ＩＩ型の投与する方法。【選択図】なし
